Yumanity Therapeutics to Host Virtual R&D Day on Monday, May 17, 2021
May 04 2021 - 8:00AM
Yumanity Therapeutics (NASDAQ: YMTX), a biopharmaceutical company
focused on the development of innovative, disease-modifying
therapies for neurodegenerative diseases, today announced that the
Company will host a virtual R&D Day on Monday, May 17, 2021 at
12:00 p.m. ET. The event will feature presentations from external
expert, David S. Russell, M.D., Ph.D., who specializes in movement
disorders, dementias and other neurodegenerative diseases, and the
Yumanity Therapeutics senior management team.
Presenters:
- David S. Russell, M.D., Ph.D., Director, Clinical Research,
Institute for Neurodegenerative Disorders; Assistant Clinical
Professor, Yale School of Medicine; Senior Medical Director,
Invicro, a Konica-Minolta Company
- Richard Peters, M.D., Ph.D., President, CEO, and Director at
Yumanity Therapeutics
- Ajay Verma, M.D., Ph.D., Executive Vice President, Head of
R&D at Yumanity Therapeutics
- Brigitte Robertson, M.D., Chief Medical Officer at Yumanity
Therapeutics
- Daniel Tardiff, Ph.D., Scientific Co-Founder and Interim Head
of Research at Yumanity Therapeutics
The live and archived webcast can be accessed under "Events
& Presentations" in the Investor Relations section of the
Company's website at
https://www.yumanity.com/investor-relations/events-presentations/.
Please log in approximately 5-10 minutes prior to the event to
register and to download and install any necessary
software. A replay of the webcast will be available for
60 days following the event.
About Yumanity TherapeuticsYumanity
Therapeutics is a clinical-stage biopharmaceutical company
dedicated to accelerating the revolution in the treatment of
neurodegenerative diseases through its scientific foundation and
drug discovery platform. The Company’s most advanced product
candidate, YTX-7739, is currently in Phase 1 clinical development
for Parkinson’s disease. Yumanity’s drug discovery platform is
designed to enable the Company to rapidly screen for potential
disease-modifying therapies by overcoming toxicity of misfolded
proteins in neurogenerative diseases. Yumanity’s pipeline consists
of additional programs focused on Lewy body dementia, multi-system
atrophy, amyotrophic lateral sclerosis (ALS or Lou Gehrig’s
disease), frontotemporal lobar dementia (FTLD), and Alzheimer’s
disease. For more information, please visit www.yumanity.com.
Investors:Burns McClellan, Inc.Lee
Rothlroth@burnsmc.com (212) 213-0006
Media:Burns McClellan, Inc.Ryo Imai / Robert
Flamm, Ph.D.rimai@burnsmc.com / rflamm@burnsmc.com (212)
213-0006
Yumanity Therapeutics (NASDAQ:YMTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Yumanity Therapeutics (NASDAQ:YMTX)
Historical Stock Chart
From Jul 2023 to Jul 2024